APOA1 and arteriosclerosis: As preparation of ApoA-I from human plasma is time-consuming, various genetic variants of ApoA-I (Terasaka et al., 2003; Nicholls et al., 2018a) or recombinant ApoA-I (Tardif et al., 2014; Nicholls et al., 2018b) have been used to replace human plasma ApoA-I to obtain reconstituted HDL or synthetic HDL (sHDL) particles with similar arteriosclerosis protective effects as endogenous HDL.